“Bristol Myers Squibb announced positive results from the Phase 3b/4 Psoriatyk Scalp study evaluating deucravacitinib in the treatment of patients with moderate to severe scalp psoriasis, including those with less extensive psoriasis.” This is what we read in a note issued on Monday 7 October 2024, in which the company highlighted that «the primary endpoint was reached, with a statistically significant improvement in the Physician’s Global Assessment (ss-PGA) specific for the scalp of 0 or 1 (clear/almost clear) at 16 weeks, with three times more patients achieving ss-Pga 0/1 with deucravacitinib treatment compared to those treated with placebo (48.5% vs 13.7 %, respectively, p«Safe and effective oral treatment»
Mark Lebwohl, Md., Chair of Clinical Therapeutics at the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai, explained that “approximately 80% of patients with plaque psoriasis have scalp involvement and usually experiences itching, scaling, pain and bleeding, which significantly reduce the quality of life. These new results confirm that deucravacitinib is a safe and effective once-daily oral treatment for people with moderate to severe psoriasis involving high-impact areas such as the scalp.”
[Se non vuoi perdere tutte le novità iscriviti gratis alla newsletter di FarmaciaVirtuale.it. Arriva nella tua casella email alle 7 del mattino. Apri questo link]
Potential to be a systemic therapy
According to Daniel Quirk, Md, Mph, Mba, senior vice president, Worldwide Immunology and Neuroscience medical affairs, Bristol Myers Squibb, “These data further demonstrate the safety and efficacy of deucravacitinib in the treatment of psoriasis in high-impact areas, such as the scalp scalp, and include the first analysis from our Rephlect registry providing evidence highlighting the real-world benefit of deucravacitinib in the treatment of moderate to severe plaque psoriasis. We believe that deucravacitinib has the potential to be a systemic therapy that clinicians can rely on to treat adult patients with moderate to severe plaque psoriasis, especially with scalp involvement. Overall, these promising results support once-daily deucravacitinib as a potential standard of care as we continue to drive Tyk2 innovation.”
